K-V Pharma, Hologic Eye $60M Deal To End Makena Feud

Law360, New York (December 6, 2012, 1:54 PM EST) -- K-V Pharmaceutical Co. reached a major milestone in its Chapter 11 case Wednesday, asking a New York bankruptcy judge to approve a $60 million settlement with Hologic Inc. to end their dispute over rights to the debtor's biggest asset, preterm-birth drug Makena.

K-V asked U.S. Bankruptcy Judge Allan L. Gropper to approve the settlement with Hologic and affiliate Cytyc Prenatal Products Corp. over Makena, the rights, title and interest in which K-V purchased from the Hologic parties under a 2008 asset purchase agreement. K-V filed for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.